FDA panel scrutinizes safety of anti-anemia drugs.
Randal
Judith
J
D000329:Advertising; D000740:Anemia / Q000188:drug therapy* / Q000209:etiology* / Q000517:prevention & control; D000068256:Darbepoetin alfa; D004921:Erythropoietin / Q000009:adverse effects / Q000031:analogs & derivatives*; D006397:Hematinics / Q000009:adverse effects*; D006801:Humans; D015337:Multicenter Studies as Topic; D009369:Neoplasms / Q000150:complications* / Q000628:therapy; D011379:Prognosis; D016032:Randomized Controlled Trials as Topic; D011994:Recombinant Proteins; D014481:United States; D014486:United States Food and Drug Administration
D006397:Hematinics; D011994:Recombinant Proteins; D004921:Erythropoietin; D000068256:Darbepoetin alfa